Literature DB >> 23926099

The relaxin receptor (RXFP1) utilizes hydrophobic moieties on a signaling surface of its N-terminal low density lipoprotein class A module to mediate receptor activation.

Roy C K Kong1, Emma J Petrie, Biswaranjan Mohanty, Jason Ling, Jeremy C Y Lee, Paul R Gooley, Ross A D Bathgate.   

Abstract

The peptide hormone relaxin is showing potential as a treatment for acute heart failure. Although it is known that relaxin mediates its actions through the G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), little is known about the molecular mechanisms by which relaxin binding results in receptor activation. Previous studies have highlighted that the unique N-terminal low density lipoprotein class A (LDLa) module of RXFP1 is essential for receptor activation, and it has been hypothesized that this module is the true "ligand" of the receptor that directs the conformational changes necessary for G protein coupling. In this study, we confirmed that an RXFP1 receptor lacking the LDLa module binds ligand normally but cannot signal through any characterized G protein-coupled receptor signaling pathway. Furthermore, we comprehensively examined the contributions of amino acids in the LDLa module to RXFP1 activity using both gain-of-function and loss-of-function mutational analysis together with NMR structural analysis of recombinant LDLa modules. Gain-of-function studies with an inactive RXFP1 chimera containing the LDLa module of the human LDL receptor (LB2) demonstrated two key N-terminal regions of the module that were able to rescue receptor signaling. Loss-of-function mutations of residues in these regions demonstrated that Leu-7, Tyr-9, and Lys-17 all contributed to the ability of the LDLa module to drive receptor activation, and judicious amino acid substitutions suggested this involves hydrophobic interactions. Our results demonstrate that these key residues contribute to interactions driving the active receptor conformation, providing further evidence of a unique mode of G protein-coupled receptor activation.

Entities:  

Keywords:  G Protein-coupled Receptors (GPCR); NMR; Peptide Hormones; Peptides; Protein Structure; RXFP1; Relaxin

Mesh:

Substances:

Year:  2013        PMID: 23926099      PMCID: PMC3784725          DOI: 10.1074/jbc.M113.499640

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA.

Authors:  Torsten Herrmann; Peter Güntert; Kurt Wüthrich
Journal:  J Mol Biol       Date:  2002-05-24       Impact factor: 5.469

2.  The human LGR7 low-density lipoprotein class A module requires calcium for structure.

Authors:  Emma J Hopkins; Ross A Bathgate; Paul R Gooley
Journal:  Ann N Y Acad Sci       Date:  2005-05       Impact factor: 5.691

3.  Overview of the retrovirus transduction system.

Authors:  C Cepko; W Pear
Journal:  Curr Protoc Mol Biol       Date:  2001-05

4.  The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein receptor class A module and identification of key residues in the N-terminal region of the module that mediate receptor activation.

Authors:  Emma J Hopkins; Sharon Layfield; Tania Ferraro; Ross A D Bathgate; Paul R Gooley
Journal:  J Biol Chem       Date:  2006-12-04       Impact factor: 5.157

Review 5.  International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides.

Authors:  Ross A Bathgate; Richard Ivell; Barbara M Sanborn; O David Sherwood; Roger J Summers
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

6.  Characterization of two relaxin genes in the chimpanzee.

Authors:  B A Evans; P Fu; G W Tregear
Journal:  J Endocrinol       Date:  1994-03       Impact factor: 4.286

7.  Torsion angle dynamics for NMR structure calculation with the new program DYANA.

Authors:  P Güntert; C Mumenthaler; K Wüthrich
Journal:  J Mol Biol       Date:  1997-10-17       Impact factor: 5.469

8.  Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules.

Authors:  Daniel J Scott; Sharon Layfield; Yan Yan; Satoko Sudo; Aaron J W Hsueh; Geoffrey W Tregear; Ross A D Bathgate
Journal:  J Biol Chem       Date:  2006-09-08       Impact factor: 5.157

9.  T222P mutation of the insulin-like 3 hormone receptor LGR8 is associated with testicular maldescent and hinders receptor expression on the cell surface membrane.

Authors:  Natalia V Bogatcheva; Alberto Ferlin; Shu Feng; Anne Truong; Lisa Gianesello; Carlo Foresta; Alexander I Agoulnik
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-08-22       Impact factor: 4.310

10.  Cooperative binding of insulin-like Peptide 3 to a dimeric relaxin family peptide receptor 2.

Authors:  Angela Manegold Svendsen; Milka Vrecl; Tina M Ellis; Anders Heding; Jesper Bøggild Kristensen; John D Wade; Ross A D Bathgate; Pierre De Meyts; Jane Nøhr
Journal:  Endocrinology       Date:  2007-12-06       Impact factor: 4.736

View more
  15 in total

Review 1.  Heart Disease and Relaxin: New Actions for an Old Hormone.

Authors:  Teja Devarakonda; Fadi N Salloum
Journal:  Trends Endocrinol Metab       Date:  2018-03-08       Impact factor: 12.015

Review 2.  Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1.

Authors:  Alexander I Agoulnik; Irina U Agoulnik; Xin Hu; Juan Marugan
Journal:  Br J Pharmacol       Date:  2016-11-30       Impact factor: 8.739

3.  Investigation of interactions at the extracellular loops of the relaxin family peptide receptor 1 (RXFP1).

Authors:  Natalie A Diepenhorst; Emma J Petrie; Catherine Z Chen; Amy Wang; Mohammed Akhter Hossain; Ross A D Bathgate; Paul R Gooley
Journal:  J Biol Chem       Date:  2014-10-28       Impact factor: 5.157

Review 4.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

5.  Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile.

Authors:  Kenneth J Wilson; Jingbo Xiao; Catherine Z Chen; Zaohua Huang; Irina U Agoulnik; Marc Ferrer; Noel Southall; Xin Hu; Wei Zheng; Xin Xu; Amy Wang; Courtney Myhr; Elena Barnaeva; Emmett R George; Alexander I Agoulnik; Juan J Marugan
Journal:  Eur J Med Chem       Date:  2018-06-07       Impact factor: 6.514

6.  The complex binding mode of the peptide hormone H2 relaxin to its receptor RXFP1.

Authors:  Ashish Sethi; Shoni Bruell; Nitin Patil; Mohammed Akhter Hossain; Daniel J Scott; Emma J Petrie; Ross A D Bathgate; Paul R Gooley
Journal:  Nat Commun       Date:  2016-04-18       Impact factor: 14.919

Review 7.  In a Class of Their Own - RXFP1 and RXFP2 are Unique Members of the LGR Family.

Authors:  Emma J Petrie; Samantha Lagaida; Ashish Sethi; Ross A D Bathgate; Paul R Gooley
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-07       Impact factor: 5.555

8.  Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290.

Authors:  Zaohua Huang; Courtney Myhr; Ross A D Bathgate; Brian A Ho; Amaya Bueno; Xin Hu; Jingbo Xiao; Noel Southall; Elena Barnaeva; Irina U Agoulnik; Juan J Marugan; Marc Ferrer; Alexander I Agoulnik
Journal:  Front Endocrinol (Lausanne)       Date:  2015-08-17       Impact factor: 5.555

9.  Chimeric RXFP1 and RXFP2 Receptors Highlight the Similar Mechanism of Activation Utilizing Their N-Terminal Low-Density Lipoprotein Class A Modules.

Authors:  Shoni Bruell; Roy C K Kong; Emma J Petrie; Brad Hoare; John D Wade; Daniel J Scott; Paul R Gooley; Ross A D Bathgate
Journal:  Front Endocrinol (Lausanne)       Date:  2013-11-11       Impact factor: 5.555

10.  In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis.

Authors:  Andrew McBride; Anna M Hoy; Mark J Bamford; Danuta E Mossakowska; Martin P Ruediger; Jeremy Griggs; Sapna Desai; Kate Simpson; Ivan Caballero-Hernandez; John P Iredale; Theresa Pell; Rebecca L Aucott; Duncan S Holmes; Scott P Webster; Jonathan A Fallowfield
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.